Open Orphan: Leveraging expertise and relationships for growth
Open Orphan (ORPH) is targeting rapid scale-up and profitability in the dynamic European orphan and rare disease consulting sector via acquisitions and organic means. The sector is reported to be growing at circa 11%, double the growth rate of the broader pharma market. The company’s Venn Life Sciences consulting arm, which counts an array of leading biopharma companies among its customers, is advancing its strategy of signing up long term partnerships with industry clients, providing substantial revenue prospects. In parallel, the company is close to launching its pioneering European rare disease, advocacy-led Genomic Health DataBANK platform and has signed five biopharma early adopters to trial its analytical capabilities.
Quick facts: Open Orphan PLC
Price: 6.35 GBX
Market Cap: £16.17 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...FOR OUR FULL DISCLAIMER CLICK HERE
LEGAL NOTICE – IMPORTANT – PLEASE READ:
Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...FOR OUR FULL DISCLAIMER CLICK HERE